Eli Lilly's Zepatide Success in Sleep Apnea Trial and Market Reactions

Eli Lilly's weight loss therapy, Zepatide, achieves main goals in Phase 3 trials for patients with obesity and obstructive sleep apnea, showing promising results in reducing primary and secondary endpoints. The chapter also delves into market reactions, highlighting stocks to watch and mentioning the impact of the Fed chairman's remarks on stock and bond markets.